INOVIO PHARMACEUTICALS, INC. (INO) research
INOVIO PHARMACEUTICALS, INC.- Sector
- Biotechnology
- Last price
- $1.24
- As of
INOVIO PHARMACEUTICALS, INC. (INO): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-12.
As of . Source: SEC EDGAR filings for INO. Method and limitations.
Share the INO intelligence card
See INO live in the terminal
Track INO's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live INO terminal, freeActive signals for INO
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +612% to INO (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +88% to INO (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +438% to INO (2026Q2)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +218% to INO (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +438% to INO (2026Q2)
FREE, NO ACCOUNT
Every signal on INO, as it fires
You are seeing 5 of 17 signals recorded on INO since 2026-05-29.
The five above all landed on 2026-09-06. The other 12 were recorded on 3 other days. 13 of the 17 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in INO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 45773H409 · 2026Q2 | $1.5M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 45773H409 · 2026Q2 | $1.4M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 45773H409 · 2026Q2 | $876K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 45773H409 · 2026Q2 | $397K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 45773H409 · 2026Q2 | $266K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, INO
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
INO mentioned in Kresmion daily briefs
INO against its peers
INO's operating margin of -132871.3% ranks in the 7th percentile of 6 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | INO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 65343 USD | 817329 USD | 39 | 8 |
| Operating margin | -132871.3% | -2002.3% | 7 | 6 |
| Net margin | -130000.0% | -2928.8% | 6 | 7 |
| Return on equity | -352.5% | -87.9% | 9 | 15 |
Peers (18): MIST, KZIA, HURA, OKUR, NMRA, CNTB, PMN, MNOV, BMEA, UNCY, NAUT, CBUS, BDTX, VTVT, VXRT, NRXP, ENGN, TNYA. Left out: CNXU (no annual filing), TLSA (period gap). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (INO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more INO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to INOand get the insider, 13F, options, and confluence read in one view.